• Fangchinoline Restores Lysosomal Biogenesis to Block H1N1 In

  2026-05-05

  This study demonstrates that fangchinoline activates TFEB-driven lysosomal biogenesis, counteracting H1N1 influenza virus strategies that disrupt lysosomal function. The findings identify a novel lysosome-centered antiviral mechanism, expanding potential therapeutic strategies against viral immune evasion.

• Amitriptyline HCl: Technical Guide for Neuropharmacology Res

  2026-05-04

  Amitriptyline HCl is a validated tricyclic compound used for targeted neurotransmitter receptor modulation in neuropharmacology and mood disorder research. This product provides reliable solubility and receptor inhibition benchmarks for experimental designs but should not be used for applications outside validated CNS research models. Its workflow is optimized for precision, solubility, and purity under controlled conditions.

• Reliable mRNA Delivery with EZ Cap™ Cy5 EGFP mRNA (5-moUTP)

  2026-05-04

  This article addresses persistent challenges in cell-based assays—such as inconsistent transfection and unreliable viability readouts—by spotlighting the advanced features of EZ Cap™ Cy5 EGFP mRNA (5-moUTP) (SKU R1011). We explore evidence-backed scenarios where its dual-fluorescent labeling, Cap 1 structure, and immune-silent chemistry drive reproducible, high-sensitivity gene delivery and functional protein expression. Researchers gain practical, data-driven answers for optimizing workflow efficiency and data reliability.

• PTH (1-34) (Human): Mechanistic Leverage for Translational R

  2026-05-03

  Explore how Parathyroid hormone (1-34) (human) enables mechanistic dissection of bone and cardiovascular calcification, with actionable guidance for translational models and critical insights from recent CKD-related valvular calcification studies.

• I-BET151 (GSK1210151A): Selective BET Inhibitor Evidence Rev

  2026-05-02

  I-BET151 (GSK1210151A) is a potent, selective BET bromodomain inhibitor for cancer research. It targets BRD2, BRD3, and BRD4, disrupting transcriptional programs central to tumorigenesis and inflammation. This review details its mechanism, benchmarks in apoptosis and cell cycle arrest assays, and integration into modern cancer biology workflows.

• DMH-1 as a Precision ALK2 Inhibitor: Unlocking Controlled Ce

  2026-05-02

  Explore how DMH-1, a potent ALK2 inhibitor, enables unprecedented control over cell differentiation and proliferation in organoid and non-small cell lung cancer research. This article delivers actionable guidance and deep analysis for optimizing experimental outcomes.

• Protease and Phosphatase Inhibitor Cocktail in Protein Extra

  2026-05-01

  Unlock reproducible protein extraction and phosphorylation preservation with the EDTA-free Protease and Phosphatase Inhibitor Cocktail. Discover workflow advances and troubleshooting strategies for sensitive cell signaling and cardiac differentiation assays.

• G007-LK Tankyrase 1/2 Inhibitor: Precision Tools for Wnt Pat

  2026-04-30

  G007-LK offers researchers a robust, selective means to inhibit tankyrase 1/2 and dissect Wnt/β-catenin and Hippo signaling in APC-mutant colorectal cancer and liver cancer models. This article details experimental workflows, protocol refinements, and practical troubleshooting for maximizing data quality with G007-LK, leveraging insights from both peer-reviewed and workflow-driven sources.

• BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist I

  2026-04-30

  BIIE 0246 is a potent neuropeptide Y Y2 receptor antagonist with nanomolar affinity, enabling precise modulation of presynaptic inhibition and feeding behavior in neuroscience research. Its validated specificity and robust in vivo effects make it a benchmark tool for dissecting NPY Y2 receptor–mediated pathways.

• A40926: Dalbavancin Precursor for Advanced Antibacterial Ass

  2026-04-29

  A40926, a potent dalbavancin precursor, sets a new benchmark for Gram-positive bacterial infection research and multidrug-resistant pathogen inhibition. This article delivers actionable protocols, troubleshooting strategies, and comparative insights to empower high-reproducibility in vitro and in vivo workflows using A40926 from APExBIO.

• E-64d in Lysoptosis and Beyond: Next-Gen Cysteine Protease I

  2026-04-29

  Explore how E-64d, a membrane-permeable cysteine protease inhibitor, empowers translational researchers to dissect lysoptosis and regulated cell death. This article integrates mechanistic insights, experimental protocols, and strategic guidance, highlighting recent advances in lysosome-dependent cell death, competitive positioning, and APExBIO’s product leadership. It contextualizes E-64d’s role in apoptosis, neuroprotection, and cancer models, distinguishing this analysis from standard product resources.

• Lysis Buffer: Optimizing Rapid Genotyping Kit Components for

  2026-04-28

  Unlock rapid, high-yield genomic DNA extraction from mouse tail tissue with APExBIO’s lysis buffer—a cornerstone of reliable genotyping workflows. This article demystifies protocol enhancements, troubleshooting, and the translational impact of buffer chemistry advancements for genetic research in mice.

• Machine Learning Identifies ADPGK as a Biomarker in ccRCC

  2026-04-28

  This study applies machine learning to dissect glucose metabolism pathways in clear cell renal cell carcinoma (ccRCC), identifying ADPGK as a potential diagnostic biomarker. The findings illuminate ADPGK's role in tumor invasion, metastasis, and immune microenvironment modulation, providing a foundation for future therapeutic strategies.

• Rotigotine: Mechanistic Advances and Strategic Horizons in P

  2026-04-27

  This thought-leadership article unpacks the mechanistic, translational, and experimental dimensions of Rotigotine—a dopamine D2/D3 receptor agonist—across Parkinson’s disease research. Drawing on pivotal nanoparticle delivery studies, it integrates experimental parameters, clinical translation, and competitive positioning, providing actionable insights for translational researchers while establishing APExBIO’s Rotigotine as a benchmark tool.

• A40926 in Antibiotic Innovation: Regulation, Assay Precision

  2026-04-27

  Discover how A40926, the natural dalbavancin precursor, is reshaping Gram-positive infection research. This article uniquely explores biosynthetic regulation, protocol optimization, and advanced applications in MRSA and Neisseria gonorrhoeae studies.

447 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page